A5105668328- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Kruppel-like factors research
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Medical research and treatments
- CNS Lymphoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Anesthesia and Pain Management
- Pain Mechanisms and Treatments
- Cancer Genomics and Diagnostics
- Hemoglobinopathies and Related Disorders
- Fungal Infections and Studies
- Spondyloarthritis Studies and Treatments
- Musculoskeletal Disorders and Rehabilitation
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Autopsy Techniques and Outcomes
- Ethics and bioethics in healthcare
- Click Chemistry and Applications
Hospital Del Mar
2021-2024
Instituto de Investigación Marqués de Valdecilla
2024
Asociación Colombiana de Gastroenterología
2006-2023
Universidad del Valle
2023
Duran i Reynals Hospital
2011-2022
Municipal Institute for Medical Research
2021-2022
Hospital del Mar Research Institute
2022
Institut Català d'Oncologia
2014-2021
Fundación Valle del Lili
2017
Institut d'Investigació Biomédica de Bellvitge
2014-2015
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Therefore, accurate disease risk prognostication critical for treatment decision-making. We obtained registry data from patients diagnosed MF in 60 Spanish institutions (N = 1386). These were randomly divided into training set (80%) test (20%). A...
The International Prognostic Score of thrombosis in Essential Thrombocythemia (IPSET-thrombosis) and its revised version have been proposed to guide prevention strategies. We evaluated both classifications prognosticate 1366 contemporary essential thrombocythemia (ET) patients prospectively followed from the Spanish Registry ET. cumulative incidence at 10 years, taking death as a competing risk, was 11.4%. risk significantly higher high-risk IPSET-thrombosis IPSET-thrombosis, but no...
Molecular and cytogenetic studies are essential for diagnosis prognosis in patients with myelodysplastic syndromes (MDSs). Cell-free DNA (cfDNA) analysis has been reported to be a reliable noninvasive approach detecting molecular abnormalities MDS; however, there is limited information about alterations monitoring cfDNA. We assessed the profile of cohort 70 MDS by next-generation sequencing (NGS) cfDNA compared results paired bone marrow (BM) DNA. Sequencing BM showed comparable mutational...
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm that can manifest as primary condition (primary myelofibrosis [PMF]) or after progression from polycythemia vera essential thrombocythemia (secondary [SMF]). The aberrant activation of the JAK-STAT pathway central to MF pathogenesis which caused by driver mutations in JAK2, CALR, and MPL genes. These mutations, along with additional somatic variants mainly impact epigenetic modifiers spliceosome components, shape clinical features...
Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We evaluated incidence risk factors vascular complications 1613 patients from Spanish Myelofibrosis Registry. Over a total 6981 patient-years at risk, 6.4% study population had least one thrombotic event after MF diagnosis, amounting an rate 1.65 per 100 patient-years. Prior history thrombosis, JAK2 mutation, intermediate-2/high-risk International...
The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses IM. objective of this study was correlate expression or e13a2 clinical characteristics, cumulative cytogenetic molecular IM, acquisition deep response (DMR) its duration (sDMR), progression rate (CIP), overall survival (OS),...
Hematological control, incidence of complications, and need for cytoreduction were studied in 453 patients with low-risk polycythemia vera (PV) treated phlebotomies alone. Median hematocrit value decreased from 54% at diagnosis to 45% 12 months, adequate control over time (< 45%) was observed 36%, 44%, 32% the 6, 12, 24 respectively. More than 5 per year maintenance phase required 19% patients. Worsening thrombocytosis, age > 60 years, microvascular symptoms constituted main indications...
Abstract Background and Aims A noninterventional prospective study was performed in Colombia Peru. The aim to describe the impact of access treatment on Patient‐reported outcomes (PRO) patients with Rheumatoid arthritis (RA) after failure conventional disease‐modifying antirheumatic drugs (DMARDs) real‐life conditions. Methods measured by barriers, time supply (TtS) interruption evaluating their effect changes PROs between baseline 6‐month follow‐up February 2017 November 2019. association...
Introduction:Myelofibrosis is a non-frequent chronic myeloproliferative Philadelphia-negative chromosome neoplasm. It heavy incapacitating orphan disease and associated with high morbidity mortality. In this context, indirect non-medical costs are expected to be high. The main objective of project estimate the economic burden in Spain.Methods:Thirty-three patients diagnosis myelofibrosis for at least 1 year participated questionnaire three Spanish centers. study consisted analyzing various...
Somatic mutations in ASXL1 seem to have a negative prognostic impact patients with several myeloid neoplasms, including myelofibrosis (MF). The aim of this work was determine the prevalence and profile MF.We analyzed 70 consecutive MF from 8 Spanish hospitals by means Sanger sequencing, as well JAK2, CALR, MPL mutations.ASXL1 were found 16/70 (23%) cases, most commonly p.Gly646TrpfsX12 (5/16). Most (13/16) frameshift mutations. Of 54 ASXL1- wild-type patients, 32 (59%) had at least one...